Diabetes Drugs Global Market Report 2022: Featuring AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Pfizer & More

DUBLIN, March 22, 2023 /PRNewswire/ -- The "Diabetes Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

This research study presents detailed analysis which helps investors, developers, company executives and industry participants in making decisions related to the prospects in the global diabetes drugs market and to take strategic initiatives. This report examines and offers the foremost trends prevalent in the global diabetes drugs market and the market size and forecast.

The scope of the report comprises types of therapy and geographical distribution. The types of therapy segments are further categorized into insulin, oral hypoglycemic drugs (anti-diabetic drugs), non-insulin injectable anti-diabetes drugs, and others. In-depth analysis in terms of market size and forecast is done for each segment for the duration 2020-2030, alongside particular CAGRs for the duration 2022-2030 is also presented in the report.A description of the market estimation of the above-mentioned segment for the duration 2020-2030 is covered in the scope of the report along with the individual market estimation for the respective countries in the regional segments.By type of therapy analysisIn 2021, insulin dominated the market due to continuous market entry of novel drug therapies, most convenient mode of treatment, and rising demand for targeted therapy/biological drugs. The growth of diabetes drugs market has been strongly supported by novel drug therapies like anti-diabetes drugs and more.

One major factor that contributes to the growth of diabetes drugs is increased life expectancy. As the populations are rapidly aging, the incidence and prevalence of many chronic diseases degeneration are bound to increase correspondingly, thus driving the growth in demand for diabetes drugs. Additionally, it is not just geriatric population that is making the choice for diabetes drugs, but increasing incidence is also being noticed in adolescents, which is also supporting the growth of the market.Diabetes medicine is a general treatment for the people who are suffering from diabetes. Various types of diabetes or anti-diabetes drugs are available, having their own area of action which help the patient to keep the condition under control. The way of delivery may differ, some injected directly into blood and some drugs taken orally. The global diabetes drugs market is emerging at impressive pace because of intensifying diabetic population growth, aging, unhealthy diets, obesity, and sedentary lifestyle resulting in increasing demand for diabetic drugs and enhancing the market size.Geographically, the global diabetes drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.In 2021, North America & Europe have accounted for the major share in global diabetes drugs market followed by Asia Pacific due to key driving factors such as rising prevalence of diabetes, high awareness associated with early diabetes diagnosis and treatment, and supportive reimbursement policies. The International Diabetes Federation estimates that in 2021 about 82 million people were diagnosed in Asia Pacific and about 1.1 million deaths occurred.

Due to perpetual growth in incidence of diabetes, the demand for novel drug therapies are expected to increase in the near future. During forecast period 2022 - 2030, Asia Pacific was observed as the fastest growing region due to key driving factors such as rising prevalence of diabetes in developing countries, increasing awareness associated with early diabetes diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.Historical & Forecast PeriodThis study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.Market Segmentation

Therapy

Insulin

Oral Hypoglycemic Drugs (anti-diabetes drugs)

Non-insulin Injectable Anti-diabetes Drugs

Others

Phase III (Market estimations by 2029)

ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)

ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)

Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)

Others

Tabular Presentation of Phase II (Qualitative Information)

Tabular Presentation of Phase Phase I (Qualitative Information)

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Diabetes Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Diabetes Drugs market?

Which is the largest regional market for Diabetes Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Diabetes Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Diabetes Drugs market worldwide?

Key Topics Covered: 1. Preface2. Executive Summary3. Diabetes Drugs Market: Competitive Analysis4. Diabetes Drugs Market: Macro Analysis & Market Dynamics5. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)6. North America Diabetes Drugs Market, 2020-2030, USD (Million)7. UK and European Union Diabetes Drugs Market, 2020-2030, USD (Million)8. Asia Pacific Diabetes Drugs Market, 2020-2030, USD (Million)9. Latin America Diabetes Drugs Market, 2020-2030, USD (Million)10. Middle East and Africa Diabetes Drugs Market, 2020-2030, USD (Million)11. Company ProfileCompanies Mentioned

AstraZeneca plc

Biocon Limited

Boston Therapeutics Inc.

Cadila Healthcare

Eli Lilly and Company

GlaxoSmithKline plc

Johnson & Johnson

Lupin Limited

Merck & Co. Inc.

Novartis International AG

Pfizer Inc.

Ranbaxy Laboratories Limited

Sanofi S.A.

Takeda Pharmaceutical Company Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/6fvhau

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and MarketsLaura Wood, Senior [email protected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/diabetes-drugs-global-market-report-2022-featuring-astrazeneca-eli-lilly-glaxosmithkline-merck-pfizer--more-301778633.html

SOURCE Research and Markets